This possibility would be consistent with a report documenting observed elevated intracellular cAMP and the fact that COX-2 inhibitor therapy reduces features of immune dysfunction and exhaustion in CD8+ T cells in HIV-infected persons [3]. This evidence concerns the gene CD8A and immune system disorder.